Lyell Immunopharma, Inc. Accumulated Other Comprehensive Income
Lyell Immunopharma, Inc. (LYEL) had Accumulated Other Comprehensive Income of -$158.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$158.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$9.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $242.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $201.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$158.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$9.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $242.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $201.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $57.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $158.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $291.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $760.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$397.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$404.00K 10-Q · filed 2024-05-06 |
| 2023-12-31 | -$94.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | -$1.18M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$2.38M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$3.88M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$7.60M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$10.00M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$8.35M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$6.60M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$1.62M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$65.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $73.00K 10-Q · filed 2021-08-12 |
| 2020-12-31 | $256.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |